The most recent trading session ended with Novavax (NVAX) standing at $12.91, reflecting a +1.77% shift from the previouse trading day's closing. The stock exceeded the S&P 500, which registered a ...
Novavax says the European Commission granted Marketing Authorization for its updated 2024-2025 Nuvaxovid COVID-19 vaccine. NVX-CoV2705 is an updated version of Novavax's prototype COVID-19 vaccine ...
Some results have been hidden because they may be inaccessible to you